pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

31,581 catalysts · 12,078 approval · 5,000 device 510k · 4,728 grant · 2,984 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 0 catalysts2026-08-04: 0 catalysts2026-08-05: 0 catalysts2026-08-06: 0 catalysts2026-08-07: 0 catalysts2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 14 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 11 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2014-04-04×clear all
type
  • approval12,078
  • device 510k5,000
  • grant4,728
  • 8k filing2,984
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings572
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Mar 30, 2015

    7
    ›Mar 30, 2015approval4150d agoOMEPRAZOLE — FDA approvalomeprazole DR

    Sponsor: DEXCEL PHARMA. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →omeprazole DR →fda approvals ↗
    ›Mar 31, 2015approval4149d agoSANDIMMUNE (CYCLOSPORINE) — FDA approvalRestasis

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →Restasis →fda approvals ↗
    ›Mar 31, 2015approval4149d agoSANDIMMUNE (CYCLOSPORINE) — FDA approvalRestasis

    Sponsor: NOVARTIS. Form: INJECTABLE. Route: INJECTION

    full page →Restasis →fda approvals ↗
    ›Mar 31, 2015approval4149d agoSANDIMMUNE (CYCLOSPORINE) — FDA approvalRestasis

    Sponsor: NOVARTIS. Form: SOLUTION. Route: ORAL

    full page →Restasis →fda approvals ↗
    ›Apr 2, 2015approval4147d agoERRIN (NORETHINDRONE) — FDA approvalNaari USA Inc

    Sponsor: DR REDDYS LABS SA. Form: TABLET. Route: ORAL-28

    full page →fda approvals ↗
    ›Apr 3, 2015approval4146d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalhydrocodone bitartrate ER

    Sponsor: STRIDES PHARMA. Form: TABLET. Route: ORAL

    full page →hydrocodone bitartrate ER →fda approvals ↗
    ›Apr 3, 2015approval4146d agoHYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — FDA approvalhydrocodone bitartrate ER

    Sponsor: STRIDES PHARMA. Form: TABLET. Route: ORAL

    full page →hydrocodone bitartrate ER →fda approvals ↗

    Week of Apr 6, 2015

    9
    ›Apr 6, 2015approval4143d agoDIGOXIN — FDA approvalHikma Pharmaceuticals USA Inc

    Sponsor: IMPAX LABS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 6, 2015approval

    Week of Apr 13, 2015

    29
    ›Apr 13, 2015approval4136d agoSTIVARGA (REGORAFENIB) — FDA approvalBayer AG

    Sponsor: BAYER HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 14, 2015approval

    Week of Apr 20, 2015

    5
    ›Apr 20, 2015approval4129d agoPEPCID AC (FAMOTIDINE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 20, 2015approval
    ← prev
    page 15 of 632
    next →
    4143d ago
    DIGOXIN — FDA approvalHikma Pharmaceuticals USA Inc

    Sponsor: IMPAX LABS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 6, 2015approval4143d agoHYDROMORPHONE HYDROCHLORIDE — FDA approvalSpecGx LLC

    Sponsor: PADAGIS US. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 8, 2015approval4141d agoATELVIA (RISEDRONATE SODIUM) — FDA approvalAllergan Finance LLC

    Sponsor: APIL. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 8, 2015approval4141d agoFOSAMAX (ALENDRONATE SODIUM) — FDA approvalALENDRONATE SODIUM

    Sponsor: ORGANON. Form: TABLET. Route: ORAL

    full page →ALENDRONATE SODIUM →fda approvals ↗
    ›Apr 8, 2015approval4141d agoBINOSTO (ALENDRONATE SODIUM) — FDA approvalOrganon & Co.

    Sponsor: RADIUS. Form: TABLET, EFFERVESCENT. Route: ORAL

    full page →fda approvals ↗
    ›Apr 8, 2015approval4141d agoACTONEL (RISEDRONATE SODIUM) — FDA approvalAllergan Finance LLC

    Sponsor: APIL. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 8, 2015approval4141d agoFOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval(alendronate sodium + cholecalciferol)

    Sponsor: ORGANON LLC. Form: TABLET. Route: ORAL

    full page →(alendronate sodium + cholecalciferol) →fda approvals ↗
    ›Apr 9, 2015approval4140d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    4135d ago
    OPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Apr 14, 2015approval4135d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Apr 14, 2015approval4135d agoHEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (HEPARIN SODIUM) — FDA approvalHEPARIN SODIUM

    Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

    full page →HEPARIN SODIUM →fda approvals ↗
    ›Apr 14, 2015approval4135d agoDAYTRANA (METHYLPHENIDATE) — FDA approvalNoven Pharmaceuticals Inc

    Sponsor: NOVEN PHARMS INC. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Apr 14, 2015approval4135d agoDAYTRANA (METHYLPHENIDATE) — FDA approvalNoven Pharmaceuticals Inc

    Sponsor: NOVEN PHARMS INC. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Apr 14, 2015approval4135d agoTRILEPTAL (OXCARBAZEPINE) — FDA approvalOXCARBAZEPINE

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →OXCARBAZEPINE →fda approvals ↗
    ›Apr 16, 2015approval4133d agoDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalDoxil

    Sponsor: BAXTER HLTHCARE CORP. Form: INJECTABLE, LIPOSOMAL. Route: INJECTION

    full page →Doxil →fda approvals ↗
    ›Apr 16, 2015approval4133d agoGLATOPA (GLATIRAMER ACETATE) — FDA approvalGLATIRAMER ACETATE

    Sponsor: SANDOZ. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →GLATIRAMER ACETATE →fda approvals ↗
    ›Apr 16, 2015approval4133d agoRECLAST (ZOLEDRONIC ACID) — FDA approvalZOLEDRONIC ACID

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ZOLEDRONIC ACID →fda approvals ↗
    ›Apr 16, 2015approval4133d agoPRIMAQUINE (PRIMAQUINE PHOSPHATE) — FDA approvalprimaquine phosphate

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →primaquine phosphate →fda approvals ↗
    ›Apr 16, 2015approval4133d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 16, 2015approval4133d agoTRAMADOL HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoCONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoQUILLIVANT XR (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalCOLLEGIUM PHARMACEUTICAL, INC

    Sponsor: NEXTWAVE. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoTROKENDI XR (TOPIRAMATE) — FDA approvalSUPERNUS PHARMACEUTICALS, INC.

    Sponsor: SUPERNUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoREGLAN (METOCLOPRAMIDE HYDROCHLORIDE) — FDA approvalANI PHARMACEUTICALS INC

    Sponsor: ANI PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoAFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approvalinsulin human

    Sponsor: MANNKIND. Form: POWDER. Route: INHALATION

    full page →insulin human →fda approvals ↗
    ›Apr 17, 2015approval4132d agoDIPRIVAN (PROPOFOL) — FDA approvalPROPOFOL

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →PROPOFOL →fda approvals ↗
    ›Apr 17, 2015approval4132d agoDEXTROAMPHETAMINE SULFATE — FDA approvalDEXTROAMPHETAMINE SULFATE

    Sponsor: AZURITY. Form: TABLET. Route: ORAL

    full page →DEXTROAMPHETAMINE SULFATE →fda approvals ↗
    ›Apr 17, 2015approval4132d agoICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approvalTakeda Pharmaceuticals USA Inc

    Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoDEXEDRINE SPANSULE (DEXTROAMPHETAMINE SULFATE) — FDA approvalMallinckrodt LLC

    Sponsor: IMPAX LABS INC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoFOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE) — FDA approvaldexmethylphenidate hydrochloride ER

    Sponsor: SANDOZ. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →dexmethylphenidate hydrochloride ER →fda approvals ↗
    ›Apr 17, 2015approval4132d agoDAYTRANA (METHYLPHENIDATE) — FDA approvalNoven Pharmaceuticals Inc

    Sponsor: NOVEN PHARMS INC. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoMETADATE CD (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalMETADATE CD

    Sponsor: AYTU BIOPHARMA. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →METADATE CD →fda approvals ↗
    ›Apr 17, 2015approval4132d agoVYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalTakeda Pharmaceuticals USA Inc

    Sponsor: TAKEDA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoRITALIN LA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalRITALIN LA

    Sponsor: SANDOZ. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →RITALIN LA →fda approvals ↗
    ›Apr 17, 2015approval4132d agoADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approvalTakeda Pharmaceuticals USA Inc

    Sponsor: TAKEDA PHARMS USA. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Apr 17, 2015approval4132d agoAPTENSIO XR (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalCOLLEGIUM PHARMACEUTICAL, INC

    Sponsor: RHODES PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    4129d ago
    AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approvalinsulin human

    Sponsor: MANNKIND. Form: POWDER. Route: INHALATION

    full page →insulin human →fda approvals ↗
    ›Apr 21, 2015approval4128d agoMORPHINE SULFATE — FDA approvalKapanol

    Sponsor: HIKMA. Form: SOLUTION. Route: ORAL

    full page →Kapanol →fda approvals ↗
    ›Apr 21, 2015approval4128d agoSUPPRELIN LA (HISTRELIN ACETATE) — FDA approvalEndo Pharmaceuticals Inc

    Sponsor: ENDO OPERATIONS. Form: IMPLANT. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Apr 23, 2015approval4126d agoJUXTAPID (LOMITAPIDE MESYLATE) — FDA approvalChiesi USA Inc

    Sponsor: CHIESI. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    $NVS156.33+1.37%
    $KVUE19.23+0.26%
    $NVS156.33+1.37%
    $NVS156.33+1.37%
    $OGN13.60+0.37%
    $OGN13.60+0.37%
    $OGN13.60+0.37%
    $BMY64.72+0.89%
    $NVS156.33+1.37%
    $COLL29.47+1.24%
    $AMRX18.14+0.39%
    $BMY64.72+0.89%
    $SUPN47.64+1.88%
    $AMRX18.14+0.39%
    $ANIP78.25-5.30%
    $MNKD4.1100+5.66%
    $AYTU2.2300-0.89%
    $COLL29.47+1.24%
    $MNKD4.1100+5.66%